News Novo Nordisk gets FDA okay for Wegovy pill The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of its Wegovy pill.
News Lilly points to long-lasting weight loss with orforglipron Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.
News Novo, Lilly sign MFN pricing deal with Trump administration The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.
News Lilly reveals $3bn orforglipron facility in Netherlands After so many announcements of new facility builds in the US, Eli Lilly has made a welcome commitment to a European investment.
News Lilly says oral GLP-1 could be 'foundational' diabetes drug Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.
News Lilly names Houston as site for $6.5bn API facility Lilly has named Houston as the second of four locations for new manufacturing facilities that are central to a $27bn investment programme in the US.
News US pharma tariffs of up to 100% finalised by Trump Trump signs his pharma tariffs executive order, which won't affect most large pharma groups but could deal a hefty blow to smaller companies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
